New Research Advances Understanding of Liver Diseases at The Liver Meeting® 2017

October 20, 2017


t Bristol-Myers Squibb, our mission is to deliver transformational medicines to patients with the most serious medical conditions in areas of high unmet need, including those with advanced liver diseases. Members of our teams are off to Washington, DC to attend The Liver Meeting® 2017, held by the American Association for the Study of Liver Diseases. Having made significant contributions to the treatment of chronic viral hepatitis, Bristol-Myers Squibb has a history of research in liver disease, and we continue to leverage that expertise today in our R&D programs. 

Lan M. Waxman, M.D. and Rose Christian, M.D.,

Lan M. Waxman, M.D., Development Lead, Gastrointestinal Cancers and Rose Christian, M.D., Development Lead, Fibrosis

At The Liver Meeting®, Bristol-Myers Squibb will present data on non-alcoholic steatohepatitis, or NASH. NASH is a condition marked by excess fat in the liver, which can lead to complications including scarring, cirrhosis, liver failure, liver transplant, or cancer. Currently, the condition is severely underdiagnosed and there are no approved treatments for NASH, which is expected to become one of the leading causes of liver transplantation and hepatocellular carcinoma (HCC) in the coming years. With a growing worldwide prevalence, the need for a better way to diagnose and treat NASH across the various stages of disease is very high. Read more about NASH.

Hear about our NASH Research below.

Watch this video to learn more about our NASH research.

We will also share an update on our research in HCC, the most common type of liver cancer, which is the second most common cause of cancer-related deaths worldwide. More than 700,000 people around the world are diagnosed with HCC each year. The majority of these cases are caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, making HBV/HCV the most common risk factor for liver cancer. In the foreseeable future, the rising prevalence of metabolic syndrome and NASH is expected to contribute to increased rates of HCC, which is often diagnosed in the advanced stage, where a significant unmet need exists. Read more about HCC.

In the foreseeable future, the rising prevalence of metabolic syndrome and NASH is expected to contribute to increased rates of HCC.

Finally, chronic viral hepatitis continues to be a significant health issue in many areas of the world and we continue to strive to ensure that patients who need treatment options have access to our medicines.  

We continue to work toward our goal of delivering new options to patients living with these conditions and we look forward to joining the research and advocacy community at The Liver Meeting®.